Sprint Bioscience signed an agreement to use Eli Lilly’s AI-based drug discovery platform Tunelab to support research across its portfolio. The deal reflects continued uptake of large-company AI systems by smaller biotechs seeking to accelerate hit generation and early screening workflows. While specific milestones and scope were not detailed in the brief provided, the partnership positions Sprint to leverage Tunelab’s data-driven chemistry and biology capabilities during target identification and optimization. For the biotech industry, the move is another example of how AI platforms are shifting from internal big-pharma tools to externalized collaboration assets that reduce early discovery cycle times.